Moderna Just Took a Step Closer to Its Product Launch Goal. Is the Stock a Buy?
(NASDAQ: MRNA) today is known for its one and only product: the coronavirus vaccine now known as Spikevax. But the company has big goals, aiming to launch as many as 15 new products over the next five years. The biotech has a solid pipeline, with various late-stage candidates across multiple treatment areas. So the elements are in place for Moderna to become more than a one-product company -- if all goes well during clinical trials.
And in recent days, it took a step closer to its product launch goal, reporting positive new data from a trial of the personalized cancer vaccine mRNA-4157 it developed with collaborator Merck (NYSE: MRK). The candidate, in combination with Merck's Keytruda, cut the risk of relapse by half after three years. Moderna chief executive officer Stéphane Bancel told CNBC last week that some countries could approve the therapy as early as 2025. Does this make Moderna a stock to buy now?
Image source: Getty Images.
Source Fool.com
Moderna Inc. Aktie
Die Community bevorzugt klar Moderna Inc. mit vielen Buy- und nur wenigen Sell-Einschätzungen.
Eine erhebliche Steigerung um mehr als 50% ist für Moderna Inc. mit einem Kursziel von 129 € im Vergleich zum aktuellen Kurs von 65.76 € zu erwarten.
